Patient-Centered Anticoagulation Self-Monitoring in Minority Patients

NACompletedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

February 28, 2019

Study Completion Date

February 28, 2019

Conditions
ThromboembolismBlood Coagulation DisordersCardiovascular DiseaseVascular Disease
Interventions
OTHER

Patient Self-Monitoring vs Anticoagulation Clinic

"Patient Self-Monitoring (intervention): entails 3 education sessions of 90-120 minutes each (week 0, week 2, week 4): 2 provided on site in clinic and 1 in the patient's home, during which, self-testing competency and barriers and facilitators to self-monitoring will be evaluated. Subjects will follow with weekly (or sooner, if clinically indicated) in-home self-monitoring and follow-up weekly phone calls over 6 months by clinical pharmacists to guide warfarin dosing and reinforce key educational messages.~Anticoagulation Clinic (control): subjects will have their INR tested in clinic monthly (or more frequently if clinically indicated) via the Coaguchek® point-of-care device (which is the standard of care in the Anticoagulation Clinic) and receive dosing instructions and standardized education related to warfarin by a clinical pharmacist who provides care in the Anticoagulation Clinic."

Trial Locations (1)

60612

University of Illinois at Chicago, Chicago

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

collaborator

Roche Pharma AG

INDUSTRY

lead

University of Illinois at Chicago

OTHER

NCT02776566 - Patient-Centered Anticoagulation Self-Monitoring in Minority Patients | Biotech Hunter | Biotech Hunter